Effect of oral silymarin in patients with acute hepatotoxic mushroom poisoning: an analysis of poison center data
2
Issued Date
2025-01-01
Resource Type
ISSN
15563650
eISSN
15569519
Scopus ID
2-s2.0-105024671519
Pubmed ID
41378447
Journal Title
Clinical Toxicology
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Toxicology (2025)
Suggested Citation
Tangsuwanaruk T., Tansuwannarat P., Tongpoo A., Mirin K., Trakulsrichai S. Effect of oral silymarin in patients with acute hepatotoxic mushroom poisoning: an analysis of poison center data. Clinical Toxicology (2025). doi:10.1080/15563650.2025.2586098 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113619
Title
Effect of oral silymarin in patients with acute hepatotoxic mushroom poisoning: an analysis of poison center data
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Introduction: Intravenous silibinin may reduce mortality in patients with hepatotoxic mushroom poisoning, but it is unavailable in some countries. This study aimed to evaluate the effectiveness of oral silymarin as an alternative treatment for decreasing mortality. Methods: This retrospective observational study included patients reported to Ramathibodi Poison Center, Thailand, from January 2016 to May 2024. Eligibility criteria were patients aged 15 years or older who ingested foraged mushrooms, with either onset of gastrointestinal symptoms at 5 h or more or elevated aspartate aminotransferase or alanine aminotransferase activities without identifiable causes. The primary outcome was in-hospital mortality. The secondary outcomes were acute liver failure, acute kidney injury, hospital length of stay, and adverse drug events. Multivariable risk regression and regression of means were used to estimate the adjusted risk difference while controlling for confounding variables. Results: A total of 255 patients were included, with an overall mortality of 5.1%. Thirty-three patients (12.9%) received silymarin. The mortality rate in the silymarin group was 3.0%, which is lower than the 5.4% mortality rate in the non-silymarin group. After adjusting for potential confounders, silymarin was not associated with a decrease in mortality. The incidence of acute liver failure and hospital length of stay were not reduced in the silymarin group, though the incidence of acute kidney injury was reduced (adjusted risk difference = −13.9% [95% CI: −23.6 to −4.1%]; P = 0.005). There were no adverse drug reactions. Discussion: Our findings were derived from retrospective data at a single poison center; further studies are warranted to evaluate the treatment benefits and cost-effectiveness. Conclusions: We were unable to demonstrate a reduction in mortality, acute liver failure, or hospital length of stay associated with oral silymarin use. However, it appeared to decrease the incidence of acute kidney injury.